This content is machine translated Diabetic nephropathy SGLT-2 inhibitor slows decline in glomerular filtration rate For the first time, a targeted therapy for diabetic kidney disease is available. In the CREDENCE study, canagliflozin resulted in a clinically relevant and statistically significant risk reduction for renal…
View Post 2 min This content is machine translated Diabetic foot syndrome Cold plasma pen accelerates healing Diabetic foot ulcers occur in up to 10% of all diabetics during their lifetime. A randomized controlled trial has now shown that treatment with cold atmospheric plasma promotes the healing…
View Post 1 min This content is machine translated T2DM X-CHANGE 2020 The Kidney as a Window to the Heart – Holistic Treatment of Type 2 Diabetes It has long been known that type 2 diabetes not only increases the risk of cardiovascular disease, but is also one of the main causes of kidney disease. What consequences…
View Post 5 min This content is machine translated Corona pandemic Current data on COVID-19 and diabetes In particular, older diabetics with a high BMI have an increased risk of a severe course and mortality rates are also higher compared to the general population. The interactions involved…
View Post 2 min This content is machine translated Schwartz-Bartter syndrome Effectively balancing electrolyte imbalances: focus on osmoregulation Nausea, vomiting, headaches and muscle cramps may also result from water retention. In Schwarzt-Bartter syndrome, this is triggered by ADH accumulation. The cause is usually small cell lung cancer, but…
View Post 5 min This content is machine translated Diabetic nephropathy Gliflozines may slow progression of renal failure Nephropathy as a late complication of diabetes is a common cause of renal failure requiring dialysis. In the CREDENCE trial, SGLT-2 inhibitors slowed the progression of renal dysfunction in diabetic…
View Post 4 min This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
View Post 5 min This content is machine translated Wound Management Modern pressure ulcer prophylaxis: an update Pressure ulcers are severe complications of multimorbidity and immobility. Pressure ulcer risk can be estimated using the Braden scale. Measures to relieve pressure and promote movement can reduce the incidence…
View Post 2 min This content is machine translated VERTIS-CV Study Evidence base of SGLT-2 inhibitors supplemented by further piece of the mosaic Ertugliflozin as an add-on to standard treatment was shown to be non-inferior to placebo in terms of MACE (major adverse cardiac event) in this large-scale international study. This confirmed the…
View Post 3 min This content is machine translated Diabetes Cases Type 2 diabetes mellitus with incipient kidney damage A 58-year-old preadipose patient with type 2 diabetes mellitus and other comorbidities is diagnosed with incipient renal impairment during a workup. This makes it necessary to adjust the diabetes therapy.
View Post 3 min This content is machine translated Hypothyroidism For those over 60 years of age and CHD, dose-reduced substitution. Hormone replacement therapy is still considered the standard treatment for hypothyroidism. Attention should be paid to an adequate dosage regimen. Dose reduction is indicated in those over 60 years of…
